CRH receptor antagonists: Advances and prospective

A. R. Ayala, Gary S Wand

Research output: Contribution to journalArticle

Abstract

Corticotrophin releasing hormone (CRH), a 41-amino acid peptide, is the main regulator of pituitary adrenocorticotrophic hormone (ACTH). Its secretion in humans plays a major role in the physiologic response to stress. CRH Type 1 and 2 receptors are widely distributed throughout the CNS and to a lesser extent in peripheral tissues. The CRH neurones modulate autonomic (locus ceruleus) and limbic system function. Furthermore, the presence of CRH receptors in inflammatory tissue and the placenta suggests that this neuropeptide is involved in modulation of the immune response and parturition. Hypersecretion of CRH is thought to play a pivotal role in the pathophysiology of major depression, anxiety and drug withdrawal. Therefore, antagonising CRH action has become a major therapeutic strategy for these disorders. Data from transgenic mice lacking or overexpressing CRH and preclinical studies with CRH antagonists have supported this theory. The development of a soluble, highly lipophilic and selective non-peptide CRH receptor (Type 1) antagonist remains a challenge. Elucidation of the role of the CRH Type 2 receptor will provide further insight into the specific role of this peptide in the periphery and selected areas of the CNS.

Original languageEnglish (US)
Pages (from-to)67-74
Number of pages8
JournalExpert Opinion on Therapeutic Patents
Volume10
Issue number1
StatePublished - 2000

Fingerprint

Corticotropin-Releasing Hormone Receptors
Hormone Antagonists
Corticotropin-Releasing Hormone
withdrawal
anxiety
drug
Limbic System
Peptides
Locus Coeruleus
Pituitary Hormones
Neuropeptides
Adrenocorticotropic Hormone
Placenta
Transgenic Mice
Anxiety
Parturition
Depression
Neurons
Amino Acids
Pharmaceutical Preparations

Keywords

  • Antagonist
  • Anxiety
  • Corticotrophin releasing hormone
  • Depression

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology
  • Law

Cite this

CRH receptor antagonists : Advances and prospective. / Ayala, A. R.; Wand, Gary S.

In: Expert Opinion on Therapeutic Patents, Vol. 10, No. 1, 2000, p. 67-74.

Research output: Contribution to journalArticle

@article{66b59a6d7aef420ca54346d38f7c73c0,
title = "CRH receptor antagonists: Advances and prospective",
abstract = "Corticotrophin releasing hormone (CRH), a 41-amino acid peptide, is the main regulator of pituitary adrenocorticotrophic hormone (ACTH). Its secretion in humans plays a major role in the physiologic response to stress. CRH Type 1 and 2 receptors are widely distributed throughout the CNS and to a lesser extent in peripheral tissues. The CRH neurones modulate autonomic (locus ceruleus) and limbic system function. Furthermore, the presence of CRH receptors in inflammatory tissue and the placenta suggests that this neuropeptide is involved in modulation of the immune response and parturition. Hypersecretion of CRH is thought to play a pivotal role in the pathophysiology of major depression, anxiety and drug withdrawal. Therefore, antagonising CRH action has become a major therapeutic strategy for these disorders. Data from transgenic mice lacking or overexpressing CRH and preclinical studies with CRH antagonists have supported this theory. The development of a soluble, highly lipophilic and selective non-peptide CRH receptor (Type 1) antagonist remains a challenge. Elucidation of the role of the CRH Type 2 receptor will provide further insight into the specific role of this peptide in the periphery and selected areas of the CNS.",
keywords = "Antagonist, Anxiety, Corticotrophin releasing hormone, Depression",
author = "Ayala, {A. R.} and Wand, {Gary S}",
year = "2000",
language = "English (US)",
volume = "10",
pages = "67--74",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - CRH receptor antagonists

T2 - Advances and prospective

AU - Ayala, A. R.

AU - Wand, Gary S

PY - 2000

Y1 - 2000

N2 - Corticotrophin releasing hormone (CRH), a 41-amino acid peptide, is the main regulator of pituitary adrenocorticotrophic hormone (ACTH). Its secretion in humans plays a major role in the physiologic response to stress. CRH Type 1 and 2 receptors are widely distributed throughout the CNS and to a lesser extent in peripheral tissues. The CRH neurones modulate autonomic (locus ceruleus) and limbic system function. Furthermore, the presence of CRH receptors in inflammatory tissue and the placenta suggests that this neuropeptide is involved in modulation of the immune response and parturition. Hypersecretion of CRH is thought to play a pivotal role in the pathophysiology of major depression, anxiety and drug withdrawal. Therefore, antagonising CRH action has become a major therapeutic strategy for these disorders. Data from transgenic mice lacking or overexpressing CRH and preclinical studies with CRH antagonists have supported this theory. The development of a soluble, highly lipophilic and selective non-peptide CRH receptor (Type 1) antagonist remains a challenge. Elucidation of the role of the CRH Type 2 receptor will provide further insight into the specific role of this peptide in the periphery and selected areas of the CNS.

AB - Corticotrophin releasing hormone (CRH), a 41-amino acid peptide, is the main regulator of pituitary adrenocorticotrophic hormone (ACTH). Its secretion in humans plays a major role in the physiologic response to stress. CRH Type 1 and 2 receptors are widely distributed throughout the CNS and to a lesser extent in peripheral tissues. The CRH neurones modulate autonomic (locus ceruleus) and limbic system function. Furthermore, the presence of CRH receptors in inflammatory tissue and the placenta suggests that this neuropeptide is involved in modulation of the immune response and parturition. Hypersecretion of CRH is thought to play a pivotal role in the pathophysiology of major depression, anxiety and drug withdrawal. Therefore, antagonising CRH action has become a major therapeutic strategy for these disorders. Data from transgenic mice lacking or overexpressing CRH and preclinical studies with CRH antagonists have supported this theory. The development of a soluble, highly lipophilic and selective non-peptide CRH receptor (Type 1) antagonist remains a challenge. Elucidation of the role of the CRH Type 2 receptor will provide further insight into the specific role of this peptide in the periphery and selected areas of the CNS.

KW - Antagonist

KW - Anxiety

KW - Corticotrophin releasing hormone

KW - Depression

UR - http://www.scopus.com/inward/record.url?scp=0033988513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033988513&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033988513

VL - 10

SP - 67

EP - 74

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 1

ER -